Real-world experience of spesolimab for generalized pustular psoriasis flares in adult patients: A multicenter retrospective study

Spesolimab is a novel interleukin-36 receptor inhibitor recently approved for treatment of generalized pustular psoriasis (GPP). While clinical trials have evaluated its efficacy and safety for this indication, real-world evidence (RWE) is sparse. Herein, we report real-world use of spesolimab in the clinical setting.